WO2009031575A1 - Therapeutic or prophylactic agent for posterior ocular disease comprising lithium salt as active ingredient - Google Patents

Therapeutic or prophylactic agent for posterior ocular disease comprising lithium salt as active ingredient Download PDF

Info

Publication number
WO2009031575A1
WO2009031575A1 PCT/JP2008/065857 JP2008065857W WO2009031575A1 WO 2009031575 A1 WO2009031575 A1 WO 2009031575A1 JP 2008065857 W JP2008065857 W JP 2008065857W WO 2009031575 A1 WO2009031575 A1 WO 2009031575A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
posterior ocular
lithium salt
prophylactic agent
ocular disease
Prior art date
Application number
PCT/JP2008/065857
Other languages
French (fr)
Japanese (ja)
Inventor
Shin-Ichiro Hirai
Tokiyoshi Matsushita
Tatsuji Kurose
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of WO2009031575A1 publication Critical patent/WO2009031575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A lithium salt such as lithium carbonate exhibits an excellent inhibitory effect on angiogenesis and an excellent inhibitory effect on the enhanced vascular permeability in a posterior ocular tissue such as a choroid or a retina, and is therefore useful as a therapeutic or prophylactic agent for a posterior ocular disease such as age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
PCT/JP2008/065857 2007-09-03 2008-09-03 Therapeutic or prophylactic agent for posterior ocular disease comprising lithium salt as active ingredient WO2009031575A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007227988 2007-09-03
JP2007-227988 2007-09-03

Publications (1)

Publication Number Publication Date
WO2009031575A1 true WO2009031575A1 (en) 2009-03-12

Family

ID=40428889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065857 WO2009031575A1 (en) 2007-09-03 2008-09-03 Therapeutic or prophylactic agent for posterior ocular disease comprising lithium salt as active ingredient

Country Status (2)

Country Link
JP (1) JP2009079041A (en)
WO (1) WO2009031575A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6153838B2 (en) * 2013-10-04 2017-06-28 エア・ウォーター株式会社 Vascular permeability inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066511A1 (en) * 2004-12-22 2006-06-29 The University Of Hong Kong Diazene-bridged crown ether lithium compounds and methods for their use
JP2007055999A (en) * 2005-08-24 2007-03-08 Neurotech Pharmaceuticals Co Ltd Pharmaceutical preparation for treating neurocyte death or nervous function disorder and concomitant therapy
KR20070082440A (en) * 2006-02-16 2007-08-21 주식회사 뉴로테크 A pharmaceutical preparation and combination therapy for treating neuronal death or neurological dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066511A1 (en) * 2004-12-22 2006-06-29 The University Of Hong Kong Diazene-bridged crown ether lithium compounds and methods for their use
JP2007055999A (en) * 2005-08-24 2007-03-08 Neurotech Pharmaceuticals Co Ltd Pharmaceutical preparation for treating neurocyte death or nervous function disorder and concomitant therapy
KR20070082440A (en) * 2006-02-16 2007-08-21 주식회사 뉴로테크 A pharmaceutical preparation and combination therapy for treating neuronal death or neurological dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG XIZHONG ET AL.: "Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependant mechanism", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 44, no. 1, 2003, pages 347 - 354 *

Also Published As

Publication number Publication date
JP2009079041A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2008140052A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising ropinirole or salt thereof as active ingredient
WO2008061043A3 (en) Uveoscleral shunt and methods for implanting same
WO2010093945A3 (en) Uveoscleral drug delivery implant and methods for implanting the same
WO2008141304A3 (en) Combined wavefront and topography systems and methods
WO2010083173A3 (en) Hydrophobic pseudo-endothelial implants for treating corneal edema
WO2010068281A3 (en) Contact lens drug delivery device
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2009105690A3 (en) Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
EP2585013A4 (en) Method and apparatus for integrating cataract surgery with glaucoma or astigmatism surgery
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
WO2011053801A3 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
WO2012047966A3 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
WO2006047466A3 (en) Ophthamological drugs
EA201590502A1 (en) EYE IMPLANT DELIVERY SYSTEM
WO2008030699A3 (en) System and method for resecting corneal tissue
WO2011151079A3 (en) Preparation for use in ophthalmology and retinal surgery
WO2008131282A3 (en) Biomechanical design of intracorneal inlays
WO2016109639A3 (en) Glaucoma treatment devices and methods
WO2008019417A3 (en) Treatment of ocular diseases
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
WO2008146721A1 (en) Prophylactic or therapeutic agent for age-related macular degeneration
WO2008150085A3 (en) 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
CL2007002386A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment and / or prophylaxis of selected diseases of macular degeneration, neovascularization or angiogenesis of the cornea, iris or retina, diabetic and non-diabetic retinopathy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828906

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08828906

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP